Head to head
Synchro REPLA:Y vs Splendor X (2026)
Compare purchase costs, running costs and the evidence behind each device.
Read the comparison overview
- Purchase cost
- The catalog lists $130k–$165k for Splendor X. No new-price range is on file for Synchro REPLA:Y. Check the source notes and request current quotes.
- Practice fit
- Both are listed under dual-wavelength laser. Check each model’s US regulatory status and labeled indications for your intended use.
Dual-wavelength laser
View full device profile →Dual-wavelength laser
View full device profile →Price comparison
New price range
- DEKA Synchro REPLA:Y
- Not published
- Lumenis Splendor X
- $130k–$165kSource not documented
Used asking range
- DEKA Synchro REPLA:Y
- $25k–$50kSource not documented
- Lumenis Splendor X
- $70k–$110kSource not documented
Payback calculator
- DEKA Synchro REPLA:Y
- View ROI calculator
- Lumenis Splendor X
- View ROI calculator
Next step
Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.
Browse current modelsConsumable economics
Consumable cost / lock-in
- DEKA Synchro REPLA:Y
- —
- Lumenis Splendor X
- No per-treatment disposable. The recurring cost is wear parts — handpiece lenses, flashlamp, protective windows, ceramic reflector, Nd:YAG and alexandrite rods, fibre window. Not published — Lumenis does not publish US wear-part pricing and the figures previously shown carried no dated source.
Service cost
- DEKA Synchro REPLA:Y
- Not published
- Lumenis Splendor X
- Not published
FDA clearance
FDA status & indication
- DEKA Synchro REPLA:Y
- FDA ClearedK131095
Read FDA indication wording
“5 10(K) Number (if known): _(I3IO95 Dekn Svnchro Renla*Y family of later tgtemg The DEKA Synchro Repla:Y family of laser systems is indicated for: 755mn laser: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types (Fitzpatrick I - VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of dermatological vascular lesions (such as port-wine stains, hemangiomas. telangiectasias).”
- Lumenis Splendor X
Read FDA indication wording
“The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots), cafe au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and/or yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).”
Which chains run each
Chain adoption
- DEKA Synchro REPLA:Y
- 0 recorded pairings
- Lumenis Splendor X
- 0 recorded pairings
Chains using it
- DEKA Synchro REPLA:Y
- —
- Lumenis Splendor X
- —
Approved reviews
- DEKA Synchro REPLA:Y
- 0
- Lumenis Splendor X
- 0
Specs and platform
Manufacturer
- DEKA Synchro REPLA:Y
- DEKA
- Lumenis Splendor X
- Lumenis
Built by (OEM)
- DEKA Synchro REPLA:Y
- DEKA M.E.L.A. S.r.l.
- Lumenis Splendor X
- Lumenis Be Ltd.
Category
- DEKA Synchro REPLA:Y
- Dual-wavelength laser
- Lumenis Splendor X
- Dual-wavelength laser
Technology
- DEKA Synchro REPLA:Y
- 755nm alex + 1064nm Nd:YAG (Alexandrite)
- Lumenis Splendor X
- 755+1064nm BLEND X square spot
Launch year
- DEKA Synchro REPLA:Y
- 2012
- Lumenis Splendor X
- 2018
Status
- DEKA Synchro REPLA:Y
- Legacy-used-market
- Lumenis Splendor X
- Current
Manufacturer source record
- DEKA Synchro REPLA:Y
- No linked source on file.
- Lumenis Splendor X
- No linked source on file.
Current alternatives
Current catalog models in related categories. Confirm availability and configuration with the supplier.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.